European Academy of Dermatology and Venereology (EADV), 2026

Concomitant use of glucagon-like peptide-1 receptor agonists in patients with psoriasis or hidradenitis suppurativa receiving bimekizumab: Cross-sectional analysis of US claims data

Bimekizumab patient-reported real-world impact in moderate to severe plaque psoriasis: Insights from a multi-country online survey

Bimekizumab quality of life and treatment satisfaction outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice in Germany: 1-year results from the ELEVATE observational study

Bimekizumab in routine clinical practice: Understanding baseline characteristics of patients with moderate to severe plaque psoriasis across five European countries from the ELEVATE observational study

Bimekizumab clinical outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice in Germany: 1-year results from the ELEVATE observational study

Bimekizumab efficacy in patients with moderate to severe psoriasis classified as obese or overweight: 1-year results from four phase 3/3b studies

Bimekizumab pharmacokinetics, safety and efficacy in adolescents with moderate to severe plaque psoriasis: Long-term data from the open-label BE CONNECTED phase 2 study

Bimekizumab drug survival in psoriasis: Real-world outcomes from the British Association of Dermatologists Biologics and Immunomodulators Register

Bimekizumab inhibited radiographic progression across baseline subgroups in biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase 3 study and its open-label extension

Bimekizumab efficacy & safety versus risankizumab in patients with active psoriatic arthritis: 24-week results from a head-to-head, multicentre, randomised, phase 3b study (BE BOLD)

Bimekizumab treatment in routine clinical care for psoriatic arthritis: Interim observational evidence of patient-reported outcome improvements from the European, multicentre SPEAK study

Bimekizumab Time to Meaningful Improvements in Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies

Real - world clinical characteristics and demographics of patients with hidradenitis suppurativa in Canada using AI - extracted data

Bimekizumab improves draining tunnel outcomes in patients with moderate to severe HS regardless of prior biologic use: 3-year data from BE HEARD EXT

Bimekizumab treatment reduces tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 1-year results from BE HEARD I&II

Bimekizumab effect on health-related quality of life and symptoms over 3 years: Data from BE HEARD EXT

Bimekizumab 3-year maintenance of response in Year 1 responders: Clinician-reported IHS4 scores and health-related quality of life outcomes from BE HEARD EXT

Bimekizumab efficacy on IHS4 response levels and draining tunnels by HS disease duration over 3 years: Data from BE HEARD EXT

Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 3-year results from BE HEARD EXT

Bimekizumab treatment in a real-world, prospective, non-interventional study in patients with moderate to severe hidradenitis suppurativa: Hi-LiGHT study design and baseline characteristics

Bimekizumab in hidradenitis suppurativa: Real-world physician- and patient-reported satisfaction results from Hi-BEAT in Germany

Bimekizumab demonstrated sustained improvements in pain and fatigue in patients with axial spondyloarthritis achieving early control of disease activity: 3-year results from two phase 3 studies and their open-label extension